ADP受体阻滞剂的研究进展

[1] The P2Y1receptor,necessary butnotsuf-ficient to support full ADP-induced platelet aggregation,is not the target of the drug clopidogrel. Hechler B,,Eckly A,Ohlmann P,etal. British Journal of Haematology . 1998

[2] Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin com-pared with ticlopidine in combination with aspirin after coronary stenting:. Bertrand ME,Rupprecht HJ,Urban P,et al. Circulation . 2000

[3] Role of ADP receptor P2Y12in platelet adhesion and thrombus formation in flowing blood. Remijn JA,Wu YP,Jeninqa EH,et al. Arteriosclerosis and Thrombosis . 2002

[4] Signaling events underlying thrombus for-mation. Jackson SP,,Nesbitt WS,Kulkarni S. Thrombosis and Haemostasis . 2003

[5] The in vivo pharmacological profile of CS-747,a novel antiplateletagentwith plateletADP receptor antagonistprop-erties. Atsuhiro S,,Fumitoshi A,Taketoshi O,et al. British Journal of Pharmacology . 2000

[6] Advances in signallingby extra-cellular nucleoides The role and transduction mechanisms of P2Yreceptors. Communi D,,Janssens R,Suarez-Huerta N,etal. Cellular Signalling . 2000

[7] Functional significance of adenosine5′-diphos-phate receptor(P2Y(12))in plateletactivation initiated by bindingof von Wil-lebrand factor to platelet GP Ibαinduced by conditions of high shear rate. Goto S,Tamura N,Eto K,et al. Circulation . 2002

[8] Molecular identification and character-ization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. Foster CJ,,Prosser DM,Agans JM,et al. The Journal of Clinical Investigation . 2001

[9] Blockade of the platelet P2Y12receptor by AR-C69931MX sustains coronary artery recanalization and improves the myo-cardial tissue perfusion in a canine thrombosis model. Wang K,,Zhou X,Zhou Z,et al. Arteriosclerosis and Thrombosis . 2003

[10] Identification of the platelet ADP re-ceptor targeted by antithrombotic drugs. Hollopeter G,Jantzen H,Vincent D,et al. Nature . 2001

[1] The P2Y1receptor,necessary butnotsuf-ficient to support full ADP-induced platelet aggregation,is not the target of the drug clopidogrel. Hechler B,,Eckly A,Ohlmann P,etal. British Journal of Haematology . 1998

[2] Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin com-pared with ticlopidine in combination with aspirin after coronary stenting:. Bertrand ME,Rupprecht HJ,Urban P,et al. Circulation . 2000

[3] Role of ADP receptor P2Y12in platelet adhesion and thrombus formation in flowing blood. Remijn JA,Wu YP,Jeninqa EH,et al. Arteriosclerosis and Thrombosis . 2002

[4] Signaling events underlying thrombus for-mation. Jackson SP,,Nesbitt WS,Kulkarni S. Thrombosis and Haemostasis . 2003

[5] The in vivo pharmacological profile of CS-747,a novel antiplateletagentwith plateletADP receptor antagonistprop-erties. Atsuhiro S,,Fumitoshi A,Taketoshi O,et al. British Journal of Pharmacology . 2000

[6] Advances in signallingby extra-cellular nucleoides The role and transduction mechanisms of P2Yreceptors. Communi D,,Janssens R,Suarez-Huerta N,etal. Cellular Signalling . 2000

[7] Functional significance of adenosine5′-diphos-phate receptor(P2Y(12))in plateletactivation initiated by bindingof von Wil-lebrand factor to platelet GP Ibαinduced by conditions of high shear rate. Goto S,Tamura N,Eto K,et al. Circulation . 2002

[8] Molecular identification and character-ization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. Foster CJ,,Prosser DM,Agans JM,et al. The Journal of Clinical Investigation . 2001

[9] Blockade of the platelet P2Y12receptor by AR-C69931MX sustains coronary artery recanalization and improves the myo-cardial tissue perfusion in a canine thrombosis model. Wang K,,Zhou X,Zhou Z,et al. Arteriosclerosis and Thrombosis . 2003

[10] Identification of the platelet ADP re-ceptor targeted by antithrombotic drugs. Hollopeter G,Jantzen H,Vincent D,et al. Nature . 2001